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Excess intake of fat from the diet has been shown in clinical studies to be closely associated with NASH development. 2 "Fat overload" has been shown to promote NASH in experimental animal models. 3 Of the different types of lipids, cholesterol overload promotes NASH progression in humans, 4, 5 even though cholesterol is an essential component of cell membranes and steroid hormones.
Indeed, greater deposition of cholesterol has been noted in NASH livers than in simple steatosis. 4 In addition, hypercholesterolemia has been shown to be associated with HCC development in patients with type-2 diabetes mellitus. 6 Furthermore, cholesterol consumption can increase the risk of liver cancer. 7 Thus, hypercholesterolemia caused by excess fat intake is a risk factor that exacerbates NASH and NASH-related HCC.
Several mechanisms by which cholesterol promotes NASH have been shown in experimental models. For instance, cholesterol accumulation in hepatocytes depletes glutathione levels in mitochondria, resulting in sensitization to tumor necrosis factor-α-induced cell death. 8 Cholesterol accumulation in hepatic stellate cells promotes liver fibrosis by enhancing susceptibility to Toll-like receptor-4 ligands. 9 Macrophages laden with cholesterol show an inflammatory phenotype and produce a large amount of pro-inflammatory cytokines. 10 In addition, hypercholesterolemia is associated with high levels of vascular endothelial growth factor (VEGF), 11 which can promote inflammation in experimental NASH models. 12 These data suggest that normalization of cholesterol levels may reduce the development of NASH and NASH-related HCC.
Statins and ezetimibe are cholesterol-lowering agents that inhibit the synthesis and absorption of cholesterol, respectively.
Several studies have shown that statins ameliorate NASH and its associated comorbidities. For instance, statins attenuate hepatic inflammation/fibrosis in human NASH. 13 In addition, an epidemiologic study demonstrated that use of statins reduced the prevalence of HCC in patients with diabetes mellitus. 14 Furthermore, the use of stains improved recurrence-free survival after curative liver resection for HCC. 15 In contrast, there are conflicting data on the effects of ezetimibe, an inhibitor of cholesterol transporter Niemann-Pick C1 like protein (NPC1L1), on human NASH. 16, 17 Unfortunately, little information is available on how ezetimibe prevents NASH and its associated comorbidities.
In the present study, we examined the effects of ezetimibe on the progression of steatohepatitis and liver tumors using hepatocytespecific phosphatase and tensin homolog (Pten)-deficient (Pten Δhep ) mice, which exhibit steatohepatitis and subsequent development of HCC. 18 Phosphatase and tensin homolog is a lipid and protein phosphatase which can regulate cholesterol metabolism. 18 Indeed, given free access to food and water until the end of the experiments under specific pathogen-free conditions. Mice were given standard chow (CE-7; CLEA Japan, Tokyo, Japan) or an HF diet (Oriental Yeast, Tokyo, Japan) with/without ezetimibe (50 mg/ kg diet) at the age of 8 weeks until 48 weeks of age. Mice were killed at the age of 48 weeks, and harvested samples were stored at −80°C until use. Externally visible tumors of diameter >2 mm were counted, with the diameter measured by stereomicroscopy.
To deplete hepatic macrophages, 200 μL of liposomal clodronate (ClodronateLiposome.org, Haarlem, the Netherlands) was injected (i.p.) into mice on the HF diet, as reported previously. 22 Lipid content in the HF diet is shown in Table S1 . Ezetimibe was provided by Merck (Rahway, NJ, USA).
| Histology
Staining for H&E and Sirius Red were performed according to the published protocols. 20 Immunohistochemical (IHC) and immunofluorescent analyses were undertaken using the primary antibodies listed in Table S2 according to manufacturer instructions. The NAFLD activity score was evaluated according to the work of Kleiner et al. 
| Quantitative real-time PCR
RNA was extracted from the liver and cells using TRIzol (Life Technologies Japan, Tokyo, Japan). The extracted RNA was converted to cDNA by reverse transcription. The cDNA was then subjected to PCR using the primers listed in Table S3 and LightCycler 480 SYBR Green I Master (Roche Diagnostics, Basel, Switzerland).
Gene expression was normalized to that of 18S RNA as an internal control. Data are the mean ± SE. *P < .05, n.s., not significant with 10-1000 μg/mL cholesterol (C3045; Sigma-Aldrich). Ezetimibe was used at 1 μmol/L in culture. Samples were harvested 8 hours or 24 hours after stimulation for mRNA and protein measurement, respectively. Huh7, a human hepatoma cell line, was used for cell proliferation assay according to manufacturer (MTT assay kit, Millipore, Temecula, CA, USA) instructions.
|

| Statistical analyses
Statistical analyses were carried out using one-way ANOVA or the Mann-Whitney U-test. Analyses were done employing SPSS v9.67
(IBM, Armonk, NY, USA). A value of P < .05 was considered significant.
| RE SULTS
| NPC1L1 expression in the intestine and the liver
Studies have shown that NPC1L1 functions in the intestine and liver in humans but is limited to the intestine in mice. 24 Thus, we first examined intestinal and hepatic expression of NPC1L1, the target of ezetimibe, in our model using IHC analyses. As previously reported, NPC1L1 was strongly expressed in the jejunum (data not shown) and the ileum ( Figure 1A Number n = 11 n = 11 n = 10 n = 12 n = 10 n = 11 n = 10 n = 13 blocked. In addition, these data suggested that biliary cholesterol was absorbed from the bile ducts in response to cholesterol requirement in mice, as observed in humans.
| Ezetimibe reduces cholesterol levels and improves steatohepatitis in Pten
Δhep mice on the
high-fat diet
Fat overload has been shown to promote NASH progression in an experimental model. 3 Hence, we examined the effect of the HF diet on steatohepatitis in Pten Δhep mice. The HF diet increased the liver/ body weight (%). In addition, the HF diet increased serum levels of cholesterol, but not those of TG, in Pten Δhep mice (Table 1 ). The severity of inflammation and hepatocyte ballooning was exacerbated, and the NAFLD activity score was increased by consumption of the HF diet (Figure 2A (Table 1) . Although hepatic and serum levels of TG and free fatty acids were not altered by ezetimibe treatment, ezetimibe decreased cholesterol levels in the serum and liver (Table 1 ). In addition, ezetimibe suppressed infiltration of inflammatory cells and hepatocyte ballooning (Figure 2A,B) , serum GPT levels ( Figure 2C ), the number of F4/80-positive hepatic macrophages ( Figure 2D ), gene expression of pro-inflammatory cytokines ( Figure 2E ) and liver fibrosis (Figure 2A ,F,G) in Pten Δhep mice on the HF diet. In contrast to the HF-diet group, ezetimibe did not improve steatohepatitis in the standard-diet group (Figure 2A-G) . Although food intake was decreased in the HF-diet group compared with the standard-diet group, ezetimibe did not alter food intake regardless of the diet consumed (Table S4 ). (Table 1) .
| Ezetimibe suppresses tumor growth in Pten
Next, we examined tumor-cell proliferation using IHC analyses 
| Ezetimibe inhibits angiogenesis induced by fat overload in Pten Δhep mice
We next examined the prevalence of HCC in HF diet and the ezetimibe groups. Although most of the liver tumors in Pten Δhep mice on the standard diet were precancerous adenoma at 48 weeks of age, the HF diet increased the prevalence of HCC at the same age ( Figure 4A ). Ezetimibe decreased the development of HCC at the age of 48 weeks ( Figure 4A ). However, ezetimibe treatment did not predispose these tumors to CCC ( Figure 4A ). 
| Fat overload increases hepatic expression of vascular endothelial growth factor in mice that lack inflammation and fibrosis
Inflammation and fibrosis can promote angiogenesis, so we examined whether fat overload can promote angiogenesis in mice that lack inflammation and fibrosis. In these experiments, we used albumin Cre-negative Pten f/f mice, which show a similar phenotype to wild-type mice. The HF diet induced increases in body weight (Table 1 ) and steatosis ( Figure 5A ). However, serum GPT levels
were not increased in the HF-diet group ( Figure 5B ). In addition, gene expression of pro-inflammatory markers was not altered by the HF diet ( Figure 5C ). Moreover, fibrosis was not induced by the HF diet (data not shown).
A few VEGF-positive cells were observed in the standarddiet group (Figure 5D,E) . The HF diet increased the number of VEGF-positive cells in the liver ( Figure 5D ,E) as well as serum VEGF levels ( Figure 5F ), which were similar levels to those observed in
Pten
Δhep mice on the HF diet. Ezetimibe reduced the body weight (Table 1 ) and hepatic steatosis ( Figure 5A ). Ezetimibe decreased the number of VEGF-positive cells and serum VEGF levels in the HF-diet group, but not in the standard-diet group ( Figure 5D ,E). These data suggested that fat overload promoted angiogenesis independent of inflammation. In addition, ezetimibe can inhibit the angiogenesis induced by fat overload.
| Kupffer cells increase vascular endothelial growth factor expression in response to lipoproteincholesterol
Next, we sought to determine the source of VEGF in the liver.
Double immunofluorescent staining showed that VEGF-positive cells were mainly co-localized with F4/80, a marker for macrophages. In Pten Δhep mice, Ly6C-positive macrophages are recruited to the liver from the bone marrow. 22 However, <10% of Ly6C cells 26 This is because the duration of the HF diet was longer in our study (40 weeks vs 6 weeks). Cholesterol is a key lipid that promotes HCC later, serum cholesterol levels are higher than those of control groups. 27 In contrast, a low cholesterol level is associated with a high incidence of HCC in patients with chronic infection with the hepatitis B virus. 28 In patients with chronic hepatitis B virus infection, low cholesterol levels reflect an advanced stage of liver disease, in which cholesterol synthesis is impaired in hepatocytes. These data suggest that the role of cholesterol in HCC development differs among the types of liver disease.
| D ISCUSS I ON
We showed, for the first time, that ezetimibe decreased tumor growth in the liver. We considered the primary effect of ezetimibe to be lowering of serum cholesterol levels. In an experimental NASH model using STAM mice, ezetimibe failed to reduce tumor development in the liver. 29 However, STAM mice developed hyperglycemia but not hypercholesterolemia, suggesting that the toxic effect of glucose was the primary cause of injury in STAM mice. Levels of glucose and insulin were not increased in Pten Response to Treatment in NASH (MOZART) Trial. 17 The cholesterol levels in patients with NASH enrolled in the MOZART Trial were lower than those in a Japanese study 16 in which ezetimibe showed beneficial effects in patients with NASH and hypercholesterolemia.
Thus, ezetimibe may show an optimal performance in patients with hypercholesterolemia.
Initially, we speculated that ezetimibe could reduce the num- We demonstrated that ezetimibe could reduce VEGF production by lowering cholesterol levels, as observed in statins. 13 Ezetimibe also improved hyperglycemia and hyperinsulinemia as a secondary effect in HF diet-fed control mice, in which glucose and insulin are potent inducers of VEGF. 37, 38 Recently, ezetimibe has been reported to possess additional functions, including alteration of gut microbiota 39 and autophagy, 40 which are closely associated with steatohepatitis and liver tumors. Thus, these beneficial effects of ezetimibe may also contribute to the suppression of liver tumors arising from steatohepatitis.
In conclusion, our data demonstrated that ezetimibe reduced HCC by inhibiting angiogenesis in Pten Δhep mice with hypercholesterolemia. These findings may have clinical implications because ezetimibe is used as a cholesterol-lowering agent. Clinical trials are necessary to assess the ability of ezetimibe to reduce human HCC related to steatohepatitis.
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